New England Journal Of Medicine Publishes Study Investigating Safety And Efficacy Of Baxter’s Cell-Based Pandemic, Avian Flu Vaccine
Jun 12th 2008Drug InformationBird Flu
Baxter International Inc. (NYSE: BAX) announced publication in the June 12, 2008 issue of The New England Journal of Medicine (NEJM) of data demonstrating Baxter’s candidate avian influenza (H5N1) vaccine, CELVAPAN, met Phase I/II trial endpoints for safety and immunogenicity (generating a functional immune response).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
